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Sodium (±)-5-bromo-2-(α-hydroxypentyl) benzoate (BZP) is a potential cardiovascular
drug and exerts potent neuroprotective effect against transient and long-term ischemic
stroke in rats. BZP could convert into 3-butyl-6-bromo-1(3H)-isobenzofuranone (Br-NBP)
in vitro and in vivo. However, the pharmacokinetic profiles of BZP and Br-NBP still
have not been evaluated. For the purpose of investigating the pharmacokinetic profiles,
tissue distribution, and plasma protein binding of BZP and Br-NBP, a rapid, sensitive,
and specific method based on liquid chromatography coupled to mass spectrometry
(LC-MS/MS) has been developed for determination of BZP and Br-NBP in biological
samples. The results indicated that BZP and Br-NBP showed a short elimination half-life,
and pharmacokinetic profile in rats (3, 6, and 12 mg/kg; i.v.) and beagle dogs (1, 2,
and 4 mg/kg; i.v.gtt) were obtained after single dosing of BZP. After multiple dosing of
BZP, there was no significant accumulation of BZP and Br-NBP in the plasma of rats
and beagle dogs. Following i.v. single dose (6 mg/kg) of BZP to rats, BZP and Br-NBP
were distributed rapidly into all tissues examined, with the highest concentrations of
BZP and Br-NBP in lung and kidney, respectively. The brain distribution of Br-NBP in
middle cerebral artery occlusion (MCAO) rats was more than in normal rats (P < 0.05).
The plasma protein binding degree of BZP at three concentrations (8000, 20,000, and
80,000 ng/mL) from rat, beagle dog, and human plasmawere 98.1–98.7, 88.9–92.7, and
74.8–83.7% respectively. In conclusion, both BZP and Br-NBP showed short half-life,
good dose-linear pharmacokinetic profile, wide tissue distribution, and different degree
protein binding to various species plasma. This was the first preclinical pharmacokinetic
investigation of BZP and Br-NBP in both rats and beagle dogs, which provided vital
guidance for further preclinical research and the subsequent clinical trials.
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INTRODUCTION
Ischemic stroke accounts for 75–85% of all the strokes occurring
annually in China and approximately 5.7 million people are
estimated to die of acute ischemic stroke per year worldwide
(Bravata et al., 2007; Broussalis et al., 2012). Ischemic stroke
is due to the occlusion of an artery in the cerebral circulation
by atherosclerotic plaque, thrombus or embolus. The course
of the disease is difficult to predict, but it generally involves
progressive deterioration (Beal, 2010; Holodinsky et al., 2016).
The prevalence of cerebral ischemic stroke is particularly high
and the survivors havemore or less neurological function deficits,
which give rise to a large burden on society and patients’ families
(Feigin et al., 2015; Truelsen et al., 2015; Wu et al., 2016).
1-3-n-butylphthalide (NBP), first isolated from the seeds of
celery, was a potent, and widely used drug for the treatment
of ischemic stroke in clinic, and it was approved in form of
soft capsule and infusion drip by the China Food and Drug
Administration (CFDA) in 2004 (Zhang et al., 2012; Yang et al.,
2015; Zhao et al., 2016). NBP displays neuroprotective effects,
improves cognitive impairment, and prevents neuronal cell death
after focal cerebral ischemia in mice via the c-Jun N-terminal
kinase pathway (Peng et al., 2008, 2010; Li et al., 2010). NBP
underwent extensive metabolism after oral administration, and
renal excretion was the primary elimination pathway. However,
toxic reactions may arise due to high plasma exposures of the
metabolites than that of NBP itself (Diao et al., 2013, 2014). About
28% of the patients had adverse events (AE) such as cerebral
hemorrhage, erythra, pneumonia, and liver dysfunction, which
may interrupt clinical uses of NBP. In addition, the bioavailability
being as low as 15% limits the application of NBP capsule in acute
ischemic stroke patients (Cui et al., 2013).
A larger number of NBP derivatives have been explored and
biological evaluated in order to improve the pharmacological
activities of NBP (Wang et al., 2013; Sheng et al., 2015; Yin et al.,
2016). Our previous study showed that 3-butyl-6-bromo-1(3H)-
isobenzofuranone (Br-NBP; Figure 1) could attenuate hydrogen
peroxide-induced damage and platelet aggregation (Gao et al.,
2010; Wang et al., 2010; Ma et al., 2012). As the drug was
aimed to apply at the acute phase in ischemic stroke, the
ideal preparation should be injection formulation. However, the
poor water-solubility of Br-NBP limited our intention, so we
developed sodium (±)-5-bromo-2-(α-hydroxypentyl) benzoate
(BZP) (Figure 1), with improved solubility, to prepare its
injection formulation. BZP could convert to Br-NBP in major
tissues in vitro and in vivo (Tian et al., 2016).
Abbreviations: BZP, sodium (±)-5-bromo-2-(α-hydroxypentyl) benzoate;
Br-NBP, 3-butyl-6-bromo-1(3H)-isobenzofuranone; LC–MS/MS, liquid
chromatography coupled to mass spectrometry; MCAO, middle cerebral
artery occlusion; NBP, l-3-n-butylphthalide; CFDA, China Food and Drug
Administration; AE, adverse events; PHPB, potassium 2-(1-hydroxypentyl)-
benzoate; IS, internal standard; ICA, internal carotid artery; ECA, external carotid
artery; MCA, middle cerebral artery; SD, Sprague-Dawley; ESI, electrospray
ionization; MRM, multiple reaction monitoring; RSD, relative standard deviation;
AUC, the area under the plasma concentration–time curve; Cmax, the peak plasma
concentration; t1/2, elimination half-life; CLz, total plasma clearance; Vz, volume
of distribution; LLOQ, lower limit of quantification; BBB, blood-brain barrier.
FIGURE 1 | Chemical structures of BZP and Br-NBP.
BZP is an innovative drug that shows potent anti-
ischemic stroke outcomes and was approved for clinical
trials by the CFDA (the approval number 2016L01072).
Pharmacodynamic study showed that BZP could protect
neurological function and decrease infarct volume after middle
cerebral artery occlusion (MCAO) with a dose-dependent
manner in rats via NF-κB pathway and mitochondrial
apoptotic pathway. In addition, BZP markedly improve
neurological deficit and exert neuroprotective effects against
permanent focal cerebral ischemia in rats. Moreover, BZP
could inhibit platelet aggregation and improve dyskinesia
and prevent ischemic stroke in salt-sensitive rats (data not
shown).
Due to the potent therapeutic effect against ischemic stroke,
it is worthwhile to systematically investigate the preclinical
pharmacokinetics of BZP and its bioactive metabolite Br-NBP.
In light of these concerns, the primary aims of current work were
to (1) investigate the non-clinical pharmacokinetic properties
of BZP and Br-NBP in rats and beagle dogs. (2) Evaluate the
tissue distribution of BZP and Br-NBP in rats. (3) Characterize
protein binding rates of BZP and Br-NBP in various species
plasma.
MATERIALS AND METHODS
Chemical and Reagents
BZP bulk drug (purity 99.4%), Br-NBP (purity 99.8%), and
PHPB (internal standard, IS, purity 98.5%) were acquired from
College of Chemistry and Molecular Engineering, Zhengzhou
University (Zhengzhou, China). BZP aseptic powder needle for
injection containing 50mg bulk drug with a total weight of
134mg per bottle were provided by Beijing Yiscon Technology
Co., Ltd. (Beijing, China). Potassium 2-(1-hydroxypentyl)-
benzoate, PHPB (internal standard, IS, purity 98.5%) was
synthesized at College of Chemistry and Molecular Engineering,
Zhengzhou University. NBP (internal standard, IS, purity 99.5%)
was purchased from CSPC NBP pharmaceutical Co., Ltd.
(Shijiazhuang, China). Methanol (HPLC grade) was obtained
from Fisher USA. Ammonium acetate (analytically pure)
was purchased from Sinopharm Chemical Reagent Co., Ltd.
(Shanghai, China). Purified water from a Milli-Q system
(Millipore, Bedford, MA, USA) was used throughout. All other
chemicals were of analytical grade and used without further
purifications.
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Experimental Animals
Sprague Dawley (SD) rats, weighing 200–240 g, were obtained
from Beijing Vital River Laboratory Animal Technology Co.,
Ltd. (Beijing, China). Beagle dogs, weighing 6.5–7.7 kg, were
purchased from Beijing Marshall Biotechnology Co., Ltd.
(Beijing, China).
Animals were housed under ideal laboratory conditions
(temperature 23–25◦C, 12 h light/12 h darkness cycle, 45–55%
relative humidity) and maintained on standard pellet diet and
water libitum throughout the experimental period. The animals
were fasted overnight with free access to water for at least 12 h
before administration. Prior to pharmacokinetic investigations
of BZP, beagle dogs received a series of examinations to ensure
animal health.
This study was performed according to the Guide for the Care
and Use of Laboratory Animals. All experimental procedures
reported herein were reviewed and approved by the Zhengzhou
University Animal Care and Use Committee.
Pharmacokinetic Studies
In vivo PK Profile of Rats
The BZP solution for injection was prepared by dissolving
251.5mg BZP in 50mL of 0.9% saline. The BZP solution for
infusion was prepared by dissolving 50mg BZP aseptic powder
needle for injection in 5mL of 0.9% saline.
Thirty rats were randomly divided into three groups
(n = 10, each group, half male and half female). For
single pharmacokinetic studies, the rats were treated with low
(3mg/kg), middle (6mg/kg), and high (12mg/kg) doses of BZP
via tail vein. Blood samples (200 µL) for pharmacokinetic
analyses were collected pre-dose and at 1, 5, 10, 20, 40, 70, 110,
170, 240, and 360 min post-BZP dose by orbital bleeding via
heparinized capillary tubes.
For multiple pharmacokinetic studies, the same rats of middle
dose group received multiple doses of 6 mg/kg/day for 7
consecutive days after the single-dose study. The blood samples
were collected immediately prior to dosage at days 5–6 and pre-
dose and at 1, 5, 10, 20, 40, 70, 110, 170, 240, and 360min
post-BZP dose at the last day. Plasma samples were harvested by
centrifuging the blood at 4500 rpm for 10min at 4◦C and stored
at−80◦C until analysis.
In vivo PK Profile of Beagle Dogs
Twenty-four Beagle dogs were randomly divided into three
groups (n = 8, each group, half male and half female). For
single pharmacokinetic studies, the rats were treated with
low (1mg/kg), middle (2mg/kg), and high (4mg/kg) doses of
BZP solution for infusion via forelimb vein. The volume for
intravenous drip was 50mL and the time was 20min. Blood
samples (250 µL) for pharmacokinetic analyses were collected at
2, 7, and 13min during the intravenous drip and at 0, 5, 10, 20,
30, 40, 60, 80, 110, 140, and 180min post-BZP dose by hind limb
vein bleeding via heparinized capillary tubes.
For multiple pharmacokinetic studies, the same beagle dogs
of the middle dose group received multiple doses of 2mg/kg/day
for 7 consecutive days after the single-dose study. The beagle dogs
were free access to water and food at 2 h after intravenous drip.
The blood samples were collected immediately prior to dosage at
days 5–6 and collected at 2, 7, and 13min during the intravenous
drip and at 0, 5, 10, 20, 30, 40, 60, 80, 110, 140, and 180min post-
BZP dose at the last day. Sample preparation was consist with
those described previously.
Tissue Distribution
Tissue Distribution of Rats
Thirty rats were randomly divided into five groups (n = 6,
each group, half male and half female), which were treated with
a single intravenous administration of BZP (6mg/kg).Tissues
(lung, small intestine, spleen, ovary, large intestine, kidney, liver,
heart, stomach, fat, testicles, brain, and muscle) were promptly
harvested at 1, 10, 20, 50, and 110min (six rats/time point) and
thoroughly in ice cold saline to eliminate blood and other content
and blotted dry with filter paper. An accurately weighted amount
of each tissue samples were homogenized in methanol-water
(50:50, v/v) solution (5 times the tissue weight, w/v) and stored
at−80◦C until analysis.
Tissue Distribution of Brain in MCAO Rats and
Normal rats
Twelve male rats were randomly divided into two groups (n =
6, each group). One group was anesthetized, and the common
carotid artery was separated from the vagus nerve, and blunt
dissection was performed to isolate the internal carotid artery
(ICA), the external carotid artery (ECA), and the middle cerebral
artery (MCA). A 30-mm monofilament was introduced into the
ECA, fed distally into the ICA, and advanced approximately
18mm through the Circle of Willis to the origin of the MCA.
The monofilament was then secured into the vessel to achieve
occlusion. After 2 h of MCA occlusion, reperfusion was achieved
by withdrawal of the suture from external carotid artery. After
closing the skin incision, rats were allowed to recover from
anesthesia, returned to their cages, and allowed to move and eat
freely. The other group did not be disposed as control group.
Then two groups were intravenous received a single dose of
6mg/kg BZP. The brains were harvested at 1 and 10min and the
samples were disposed as the same with those described in tissue
distribution.
Plasma Protein Binding of BZP In vitro
Ultrafiltration method was adopted in this study, which was
widely used to determine the plasma protein binding (Wang
and Williams, 2013; Amini et al., 2014; Li et al., 2015). In
vitro experiment, binding of BZP to protein in fresh plasma
from pooled SD rat, beagle dog, and human plasma were
measured separately. Plasma samples containing BZP were
prepared in vitro. The plasma samples were spiked to give
final BZP concentrations of 8000, 20,000, and 80,000 ng/mL.
The samples were incubated for 30min at 37◦C and 400 µL
aliquots were placed into an ultrafiltration device. The samples
were centrifuged at 5000 g for 20min. Concentrations of BZP
in the filtrate were determined by the LC-MS/MS. The stability
of BZP and Br-NBP in solution was investigated and met the
requirements of this study.
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Sample Preparation
Each sample was thawed and vortexed. For every 50µL plasma
(or tissue homogenates) samples, 50µL mixed IS (consisted of
PHPB and NBP) and 150µL methanol were added. The mixture
was mixed for 1min and centrifuged for 10min at 13,000 rpm.
200 µL supernatant was centrifuged at 13,000 rpm for 5min
again. After centrifugation, supernatant was transferred to a fresh
vial and 10 µL was injected into chromatographic system for
analysis.
Bioanalytical Methods
Plasma and tissue homogenates concentrations of BZP and Br-
NBP were quantified by a sensitive and specific LC-MS/MS
method. The assays were validated according to US Food
and Drug Administration (USFDA) guidelines on bioanalytical
method validation (US Department of Health Human Services
et al., 2001).
LC-MS/MS system consisting of a Thermo Fisher ACCELA
LC system connected with a Thermo Fisher TSQ QUANTUM
ULTRA triple-quadrupole mass spectrometer with an
electrospray ionization (ESI) interface in positive and negative-
ion mode. Chromatographic separation was achieved on a
Hypersil GOLD C18 colume (5 µm, 100 × 2.1mm) maintained
at 30◦C at a flow rate of 0.2mL/min. Elution was performed by
a gradient mobile phase consisting of 5mM ammonium acetate
(A) and methanol (B). The gradient started at 55% B for 2min,
increasing linearly to 90% B within 2min, then maintained at
90% B for another 1min, afterwards level of B was decreased
back to 55% within 0.1min, then the column was equilibrated till
8min for next sample injection. The injection volume was 10µL
in partial loop mode. The parameter settings were as follows:
spray voltage of positive-ion, 3500 V; spray voltage of negative-
ion, 2500 V; capillary temperature, 350◦C; sheath gas (nitrogen),
30 arbitrary units; auxiliary gas (nitrogen), eight arbitrary
units; vaporizer temperature, room temperature. Detection
and quantification of the compounds were performed in the
multiple reaction monitoring (MRM) mode with the transitions
of m/z 285.00→85.00 for BZP and m/z 207.00→85.00 for
PHPB (IS of BZP), m/z 269.00→144.00 for Br-NBP and m/z
191.00→145.00 for NBP (IS of Br-NBP), respectively. BZP
and PHPB were measured in negative-ion and a positive ion
mode was used for quantification of Br-NBP and NBP. Thermo
Fisher LCQUAN quantitative software was used for data
analysis.
Base on the analytical conditions mentioned above, BZP,
PHPB (IS of BZP), Br-NBP, and NBP (IS of Br-NBP) were well
separated and there was no interference from plasma and tissue
homogenates. The assays for plasma and tissue homogenate
samples were linear over a range of concentrations from 5 to
10,000 ng/mL (R2 > 0.99). The lower limit of quantification
(LLOQ) value of BZP and Br-NBP both are 5 ng/mL. The lower
limit of detection (LLOD) value of BZP and Br-NBP both are
1 ng/mL. Separate sets of analytical quality control samples (for
concentrations of 10, 250, and 5000 ng/mL) were used during
plasma and tissue homogenate sample and (for concentrations
of 10, 50, and 250 ng/mL) were used to assess assay precision and
accuracy. The intra- and inter-day precision was lower than 15%
in terms of relative standard deviation (RSD). The stability results
showed plasma and tissue homogenate samples were stable in
three freeze/thaw cycles at −20 and −80◦C, 1 month at −20 and
−80◦C, 24 h at room temperature and 24 h before injection.
Pharmacokinetic Calculation and Data
Analysis
The concentration vs. time data was assessed via
non-compartmental analysis using the DAS 2.0 package
(version 2.0 pharmacokinetic software; Chinese pharmaco-
logical Assn., Beijing, China). The Cmax, AUC, and CLz data
between different groups were compared using One-way analysis
of variance (ANOVA) followed by Tukey’s post-hoc test. The
results are expressed as the mean ± SD. A value of P < 0.05 was
considered to be statistically significant. All statistical analyses
were performed with SPSS 17.0 for windows.
RESULTS
Plasma Pharmacokinetic Study
In vivo PK in Rats
Single dose of BZP in rats
The mean plasma concentration-time profiles of BZP after
administration of BZP (3, 6, and 12mg/kg, i.v.) were illustrated in
Figure 2. The pharmacokinetic parameters of BZP are presented
in Table 1. The mean Cmax and AUC0–t values of BZP were
linearly related to the dose in the range of 3–12mg/kg. The
coefficient of association was 0.9792 for dose to AUC0–t in
rats (y = 88.78x + 71.52; y refers to AUC0–t, x refers to
dose). The plasma concentration declined rapidly following the
intravenous dosing with a short t1/2. In addition, for three doses,
the AUC0–t and Cmax values of BZP for female rats were 1–2
times higher than those of the male rats (P < 0.05). As for other
major pharmacokinetic parameters such as t1/2z, CLz, and Vz, a
significant difference was observed between the low dose group
(3mg/kg) and middle dose group (6mg/kg), while no difference
was found between the middle dose group (6mg/kg) and high
dose group (12mg/kg).
Multiple dose of BZP in rats
The mean plasma concentration-time profiles of BZP after BZP
treatment (6mg/kg, once daily for 7 days, i.v.) were shown in
Figure 2. The pharmacokinetic parameters of BZP are presented
in Table 1. The Cmin values of BZP are under the LLOQ
(5 ng/mL) at 5–7 day. The Cmax and AUC0–t values of BZP
were no significant differences in female and male rats after 7
consecutive day’s administration. Compared with the parameters
after single dose of BZP (6mg/kg, i.v.), the Cmax and AUC0–t
values were much higher (P < 0.01), the CLz and Vz values were
much lower (P < 0.01), and the t1/2 values were no significant
differences after 7 consecutive day’s administration.
PK profile of Br-NBP after single dose of BZP in rats
As presented in Figure 3, Table 2, the mean Cmax and AUC0–t
values of Br-NBP were linearly related to the dose in the range
of 3–12mg/kg. The coefficient of association was 0.9386 for dose
to AUC0–t in rats (y = 21.83x). In addition, the Cmax values of
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FIGURE 2 | The mean plasma concentration-time profiles of BZP in rats. Rats received intravenous administration of BZP (A) at a single dose of 3 or 12 mg/kg
(n = 10); (B) at a dose of 6 mg/kg once for 1 day and the same dose for 7 days (n = 10). The results are the mean ± SD of the indicated number of rats.
TABLE 1 | The pharmacokinetic parameters of BZP in rats after single and multiple intravenous administration of BZP (n = 10).
PK parameters BZP (3.0mg/kg) single BZP (6.0mg/kg) single BZP (12.0mg/kg) single BZP (6.0mg/kg) multiple
Male Female Male Female Male Female Male Female
AUC0–t (mg·h/L) 302.51±51.23 462.81±50.08* 414.13±60.01 659.73± 117.10* 953.78±142.86 1159.28±337.39* 685.15± 85.79
## 856.73±179.84*##
AUC0–∞ (mg·h/L) 302.58±51.25 463.18±49.95* 414.35±60.04 660.59± 117.03* 956.86±140.82 1162.45±336.76* 685.48± 85.82
## 857.00±179.97*##
MRT0–t (min) 17.25±2.84 24.83±2.11* 22.14±2.72 22.99± 4.04* 21.16±2.20 24.09±2.95* 16.66± 0.86 20.51±3.20*
MRT0–∞ (min) 17.31±2.86 25.16±2.22* 22.35±2.65 23.60± 3.57* 22.88±1.84 25.27±2.46* 16.86± 0.83 20.63±3.27*
t1/2z (min) 21.84±1.01 41.23±8.66* 42.59±10.03
1 62.62± 24.61*1 81.99±36.2711 67.18±24.01*11 45.12± 11.34 38.90±6.54*
CLz (L/min·kg) 0.010±0.002 0.007±0.001 0.015±0.002
1 0.009± 0.0021 0.013±0.0021 0.009±0.0031 0.009± 0.001## 0.007±0.002##
Vz (L/kg) 0.32±0.05 0.39±0.11 0.90±0.25
11 0.87± 0.4711 1.57±0.8211 0.94±0.49*11 0.57± 0.14## 0.41±0.10*##
Cmax 25‚527±2946 32‚123±2644* 34‚641±5778 43‚810± 5894* 74‚785±6822 90‚434±11‚408* 58‚309± 4158
## 56‚888±13‚774*##
*P < 0.05, compared with male group; ∆P < 0.05, ∆∆P < 0.01, compared with the group (3.0mg/kg); ##P < 0.01, compared with the single group (6.0mg/kg).
Br-NBP were no significant differences between female and male
rats in the dose of 3–12mg/kg. The AUC0–t values of Br-NBP
were no significant differences in female and male rats in 6 and
12mg/kg. But for 3mg/kg, the AUC0–t values of Br-NBP were
higher in female rats than in male rats (P < 0.05). Similar to
BZP, other major pharmacokinetic parameters (t1/2z, CLz, and
Vz) for Br-NBP were significantly different between low dose
group (3mg/kg) and middle dose group (6mg/kg), while were
same between middle dose group (6mg/kg) and high dose group
(12mg/kg).
PK profile of Br-NBP after multiple dose of BZP in rats
As shown in Figure 3, Table 2, the Cmin values of Br-NBP were
under the LLOQ (5 ng/mL) at 5–7 day. The Cmax and AUC0–t
values of Br-NBP had no significant differences in female and
male rats after 7 consecutive day’s administration. Compared
with the parameters after single dose of BZP (6mg/kg, i.v.),
the Cmax, AUC0–t, CLz, and the t1/2 values of Br-NBP had no
significant differences after 7 consecutive day’s administration.
In vivo PK Profile in Beagle Dogs
Single dose of BZP in beagle dogs
The beagle dogs in the test groups were intravenous drip
with BZP at 1, 2, or 4 mg/kg followed by analysis of
BZP concentration in plasma. The plots of mean plasma
concentration of BZP in dogs were depicted in Figure 4. A
summary of the pharmacokinetic parameters for BZP in beagle
dogs is shown in Table 3. The mean Cmax and AUC0–t values of
BZP were linearly related to the dose in the range of 1–4mg/kg.
The coefficient of association was 0.9124 for dose to AUC0–t in
beagle dogs (y= 43.103x+ 55.3). In addition, for three doses, the
AUC0–t and Cmax values of BZP had no significant differences in
female and male beagle dogs.
Multiple dose of BZP in beagle dogs
As presented in Figure 4, Table 3, the Cmin values of BZP were
under the LLOQ (5 ng/mL) at 5–7 day. The Cmax and AUC0–t
values of BZP had no significant differences in female and male
rats after 7 consecutive day’s administration. Compared with
the parameters after single dose of BZP (2mg/kg, i.v.gtt), the
Cmax and AUC0–t, CLz, Vz, and t1/2 values had no significant
differences after 7 consecutive day’s administration.
PK profile of Br-NBP after single dose of BZP in beagle dogs
The mean plasma concentration-time profiles of Br-NBP after
administration of BZP (1, 2, and 4mg/kg, i.v.gtt) were illustrated
in Figure 5. The pharmacokinetic parameters of Br-NBP were
Frontiers in Pharmacology | www.frontiersin.org 5 August 2016 | Volume 7 | Article 255
Tian et al. Preclinical Pharmacokinetics of BZP
FIGURE 3 | The mean plasma concentration time profiles of Br-NBP in rats. Rats received intravenous administration of BZP (A) at a single dose of 3 or
12 mg/kg (n = 10); (B) at a dose of 6 mg/kg once for 1 day and the same dose for 7 days (n = 10). The results are the mean ± SD of the indicated number of rats.
TABLE 2 | The pharmacokinetic parameters of Br-NBP in rats after single and multiple intravenous administration of BZP (n = 10).
PK parameters BZP (3.0 mg/kg) single BZP (6.0 mg/kg) single BZP (12.0 mg/kg) single BZP (6.0 mg/kg) multiple
Male Female Male Female Male Female Male Female
AUC0–t (mg·h/L) 56.09±2.98 71.73±10.83* 145.43±22.33 174.18±36.35 222.78±56.04 273.12±39.52 179.54± 12.73 151.52±70.08
AUC0–∞ (mg·h/L) 56.23±3.04 71.99±10.75* 145.67±22.37 174.62±36.48 223.63±55.72 275.07±39.90 179.96± 12.76 152.05±69.90
MRT0–t (min) 15.84±3.45 19.24±4.62 14.81±1.94 15.79±1.78 19.75±1.66 22.66±5.08 15.53± 2.37 19.18±2.88
MRT0–∞ (min) 16.26±3.28 19.81±4.37 15.23±2.29 16.27±1.93 21.52±2.33 26.08±5.59 16.18± 2.75 20.01±3.25
t1/2z (min) 22.70±5.80 25.52±9.70* 26.78±12.37
1 24.53±3.03*1 64.86±19.5911 95.59±23.09*11 35.84± 10.48 28.74±9.21*
CLz (L/min·kg) 0.054±0.003 0.043±0.008* 0.042±0.006
1 0.035±0.008*1 0.056±0.0121 0.045±0.007*1 0.033± 0.003 0.046±0.02*
Vz (L/kg) 1.74±0.37 1.52±0.44 1.63±0.84
11 1.25±0.2511 5.48±2.5711 6.06±1.3811 1.72± 0.51 1.78±0.57
Cmax 5880±827 6359±946 15‚048±3156 15‚382±2013 22‚030±4007 20‚750±5674 16‚644± 2827 10‚438±5736
*P < 0.05, compared with male group; ∆P < 0.05, ∆∆P < 0.01, compared with the group (3.0mg/kg).
FIGURE 4 | The mean plasma concentration-time profiles of BZP in
beagle dogs. Beagle dogs received intravenous drip administration of BZP at
a single dose of 1, 2 or 4mg/kg (n = 8) and at multiple dose of 2mg/kg for
7 days (n = 8). The results are the mean ± SD of the indicated number of
beagle dogs.
presented in Table 4. The mean Cmax and AUC0–t values of Br-
NBP were linearly related to the dose in the range of 1–4mg/kg.
The coefficient of association was 0.9999 for dose to AUC0–t in
beagle dogs (y= 49.837x+ 0.62). In addition, for three doses, the
AUC0–t andCmax values of Br-NBP had no significant differences
in female andmale beagle dogs. The other major parameters such
as t1/2z, CLz, and Vz values exhibited no differences in the range
of 1–4mg/kg.
PK profile of Br-NBP after multiple dose of BZP in beagle
dogs
The mean plasma concentration-time profiles of Br-NBP after
BZP treatment (2mg/kg, once daily for 7 days, i.v.gtt) were
shown in Figure 5. The pharmacokinetic parameters of Br-NBP
are presented in Table 4. The Cmin values of Br-NBP are under
LLOQ (5 ng/mL) at 5–7 days. The Cmax and AUC0–t values
of Br-NBP were no significant differences in female and male
rats after 7 consecutive day’s administration. Compared with
the parameters after single dose of BZP (2mg/kg, i.v.gtt), the
Cmax, and AUC0–t, CLz, Vz, and t1/2 values had no significant
differences after 7 consecutive day’s administration.
Tissue Distribution
The Tissue Distribution in Rats
The tissue distribution of BZP in rats
The concentration of BZP in various tissues of rats determined at
1, 10, 20, 50, and 110 min after i.v. administration were presented
in Figure 6. At 1min after i.v. injection with a dose of 6mg/kg,
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TABLE 3 | The pharmacokinetic parameters of BZP after single and multiple intravenous drip administration of BZP in beagle dogs (n = 8).
PK parameters Single Multiple
BZP (1.0mg/kg) BZP (2.0mg/kg) BZP (4.0mg/kg) BZP (2.0mg/kg)
AUC0–t (mg·h/L) 82.98± 14.14 164.64±49.84 210.61± 67.27 146.07± 44.49
AUC0–∞ (mg·h/L) 83.10± 14.14 165.04±49.93 211.10± 67.34 146.46± 44.58
MRT0–t (min) 26.98± 3.53 25.22±1.76 23.47± 1.87* 25.36± 2.97
MRT0–∞ (min) 27.25± 3.57 25.82±1.61 24.01± 1.73*
1 25.09± 2.93
t1/2z (min) 22.26± 9.05 34.62±18.31 33.05± 6.98* 35.20± 11.70
CLz (L/min·kg) 0.012± 0.002 0.014±0.008 0.021± 0.005** 0.015± 0.005
Vz (L/kg) 0.40± 0.20 0.70±0.50 1.01± 0.45** 0.77± 0.39
Cmax (ng/mL) 3008± 651 6463±2249 8096± 2235 5235± 1244
*P < 0.05, **P < 0.01, compared with the group (1.0mg/kg); ∆P < 0.05, compared with the single dose group (2.0mg/kg).
FIGURE 5 | The mean plasma concentration-time profiles of Br-NBP in
beagle dogs. Beagle dogs received intravenous drip administration of BZP at
single dose of 1, 2 or 4mg/kg (n = 8) and at multiple dose of 2 mg/kg for
7 days (n = 8). The results are the mean ± SD of the indicated number of
beagle dogs.
different concentrations of BZP were detected in most tissues.
The highest concentration was observed in lung, followed by
small intestine, spleen, ovary, large intestine, kidney, liver, heart,
stomach, fat, testicle, brain, and muscle. With the prolonging of
time, the concentrations of BZP in most of the tissues decreased
obviously within 110min.
The tissue distribution of Br-NBP in rats
The concentration of Br-NBP in various tissues of rats
determined at 1, 10, 20, 50, and 110min after administration
were presented in Figure 7. The highest concentration was
achieved at 1min in major tissues except for brain and fat. The
concentrations of Br-NBP in brain and testicle were elevated
from 1 to 10min and declined till 110min. At 50min, the
concentration of Br-NBP in fat was highest. Elimination process
of Br-NBP from examined tissues was slower compared to BZP.
The highest concentration level was observed in kidney, followed
by lung, liver, heart, ovary, stomach, spleen, large intestine, small
intestine, muscle, brain, and lowest in testicle and fat at 1min.
With the extent of time, the concentrations of Br-NBP in most of
the tissues decreased obviously within 110min.
The AUC of BZP and Br-NBP in tissues of rats
The AUC of BZP and Br-NBP in 13 tissues were calculated
in trapezoidal method and presented in Table 5. The results
indicated that BZP could transform into Br-NBP in vivo in major
tissues of rats.
The Distribution of Brain in Normal and MCAO Rats
The concentration of BZP and Br-NBP in the brain at 1 and
10min after a single intravenous injection of BZP (6mg/kg) were
presented in Table 6. The results indicated that the concentration
of BZP had no statistical differences at 1 and 10 min in normal
and MCAO rats. But for Br-NBP, the concentration in MCAO
rats was much higher than in normal rats at 1 min (P< 0.01) and
10min (P < 0.05).
Plasma Protein Binding Assay
Figure 8 listed the plasma protein binding rates of BZP (%) in
pooled plasma samples at different concentrations from pooled
SD rat, beagle dog and human plasma. The percent binding was
found to be highest in rat plasma with 98.7, 98.4, 98.1% compared
in human plasma with 83.7, 81.8, 74.8% and in beagle dog plasma
with 92.7, 90.7, 88.9%, respectively.
DISCUSSION
BZP represents a major breakthrough for an unmet medical need
and exerts effective neuroprotective effect on cerebral ischemia-
reperfusion damage in rats. The pre-clinical pharmacokinetic
study plays an essential role in the evaluation of new drug
development. Besides, it is an important basis to evaluate the
drugs’ characteristics, quality, mechanism of action, basis of
efficacy, and toxicity actions. In addition, it can provide vital
reference information for the design and optimization of clinical
trials (Singh, 2006). As for the pre-clinical pharmacokinetic
profiles of BZP were still unclear, we carried out this study
to evaluate the pharmacokinetic parameters, tissue distribution
and plasma protein binding of BZP and Br-NBP in rodent and
non-rodent animals for the first time.
In our study, rodent and non-rodent animals were chosen as
the animal models, according to the guidelines of non-clinical
pharmacokinetic study approved by CFDA (China Food Drug
Frontiers in Pharmacology | www.frontiersin.org 7 August 2016 | Volume 7 | Article 255
Tian et al. Preclinical Pharmacokinetics of BZP
TABLE 4 | The pharmacokinetic parameters of Br-NBP in beagle dogs after single and multiple intravenous drip administration of BZP (n = 8).
PK Parameters Single Multiple
BZP (1.0mg/kg) BZP (2.0 mg/kg) BZP (4.0mg/kg) BZP (2.0mg/kg)
AUC0–t (mg·h/L) 49.86± 5.97 101.19±17.75 199.67±26.77 91.04± 14.48
AUC0–∞ (mg·h/L) 50.15± 5.98 101.69±17.92 200.91±27.15 91.52± 14.34
MRT0–t (min) 26.19± 2.87 26.84±2.55 24.51±2.19
1 27.40± 2.70
MRT0–∞ (min) 27.05± 3.39 27.84±2.71 26.10±2.14
1 28.74± 3.05
t1/2z (min) 21.57± 6.54 31.90±7.62 43.08±22.29
1 36.91± 13.29
CLz (L/min·kg) 0.020± 0.002 0.020±0.005 0.020±0.003
11 0.022± 0.003
Vz (L/kg) 0.62± 0.14 0.94±0.34 1.24±0.60
11 1.21± 0.52
Cmax (ng/mL) 1896± 303 3714±677 7436±1790 3101± 512
∆P < 0.05, ∆∆P < 0.01, compared with the group (2.0mg/kg).
FIGURE 6 | Mean concentration of BZP in 13 tissues at 1, 10, 20, 50, and 110 min after a single intravenous injection of BZP (6mg/kg) in rats. (n = 6,
mean ± SD).
Administration, 2014). We chose SD rats in rodent animals
as the anatomical features and physiological characteristics of
SD rats were similar to human. Beagle dogs were selected in
non-rodent animals, in consideration of their advanced blood
circulation system and similar pharmacology and toxicology
reaction with human (Jaiswal et al., 2014). The toxicology studies
of BZP were finished in China National Chengdu Center for
Safety Evaluation of Drugs under Good laboratory practice
of drug (GLP) conditions. The acute toxicity research results
showed that, the maximum tolerated doses of BZP were 200
and 300mg/kg after single i.v. administration to rats and beagle
dogs, respectively. After single i.v. administration to beagle dogs
(200, 300mg/kg), visible tremors, vomiting, weakness, salivation
and deep breathing symptoms were shown and could recover
in 0.25–4 h. The long-term toxicity results elaborated, the non-
toxic-effect dose level of BZP is 50mg/kg after multiple i.v.
administration to rats and beagle dogs. General transient toxic
symptoms such as head tremor, body tremor, and nervous
function toxicity can be seen and recovered in 28 days withdrawal
of the drug after multiple i.v. administration to rats and beagle
dogs. Therefore, the dose levels of BZP selected in this study
in rats were generally safe, well tolerated, and in the range of
pharmacodynamic effective doses. The conversion of rat doses
to beagle dogs equivalent doses based on body surface area was
performed in accordance with the guideline set by US FDA
[US Department of Health and Human Services (DHHS) et al.,
2005].
After intravenous administration of BZP to rats, rapid
distribution phase followed by a relatively slow elimination
phase of BZP and Br-NBP was observed in concentration-
time curves. We have investigated the effect of different
doses on the pharmacokinetic behavior of BZP and Br-NBP.
The Cmax and AUC0–t of BZP and Br-NBP increased with
dose in a dose-dependent manner, which indicated a linear
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FIGURE 7 | Mean concentration of Br-NBP in 13 tissues at 1, 10, 20, 50, and 110 min after a single intravenous injection of BZP (6mg/kg) in rats. (n = 6,
mean ± SD).
TABLE 5 | The AUCBZP and AUCBr-NBP in vivo of rats at 110min.
Tissue AUCBZP AUCBr-NBP AUCBZP+Br-NBP AUCBZP/AUCBr-NBP
(nmol·min/g) (nmol·min/g) (nmol·min/g)
Blood* 2326.44 504.36 2830.80 4.613
Brain 3.22 77.48 80.71 0.042
Spleen 34.42 113.69 148.11 0.303
Kidney 14.68 607.74 622.43 0.024
Liver 11.91 453.33 465.25 0.026
Heart 10.77 329.40 340.17 0.033
Lung 254.00 1318.30 1572.30 0.193
Ovary 76.09 636.56 712.65 0.120
Testical 49.39 79.91 129.30 0.618
Large intestine 48.60 201.22 249.82 0.242
Small intestine 62.23 177.94 240.17 0.350
Muscle 2.94 88.19 91.13 0.033
Stomach 21.25 377.24 398.49 0.056
Fat 16.30 167.18 183.48 0.098
All 2932.25 5132.55 8064.80 0.571
*For blood: 1mL ≈ 1.08 g.
pharmacokinetic profile in 3–12 mg/kg in rats. However, there
was a significant difference between the groups for other major
pharmacokinetic parameters such as t1/2z, CLz, and Vz, which
could be caused by the short t1/2 level and individual differences.
Besides, the AUC0–t ratios of BZP/Br-NBP were 6.08, 3.36, and
4.68 for 3, 6, and 12 mg/kg respectively, suggesting that the
dose may influence the transformation of BZP to Br-NBP. After
multiple administration of BZP to rats, the trough concentration
of this component could not be detected, which demonstrated
that there was no accumulation in rats. In addition, the Cmax and
AUC0–t of BZP on day 7 were significant higher than on day
1 (P < 0.05), which may be due to the enzyme self-inhibition
or other factors. The pharmacokinetic parameters and plasma
concentrations of Br-NBP between day 1 and day 7 had no
difference, which also indicated that there was no accumulation
of Br-NBP in rats.
Dose-dependent linear pharmacokinetic profiles of BZP and
Br-NBP were observed in beagle dogs after single intravenous
drip administration (1, 2, and 4mg/kg). The volume of
distribution was estimated to be more than the total body
water, demonstrating extensive distribution to tissues. The short
t1/2 value contrast to the long t1/2 of NBP (t1/2 = 249 ±
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TABLE 6 | The concentration of BZP and Br-NBP at 1 and 10 min after
single intravenous injection of BZP (6 mg/kg) in the brain of normal and
MCAO rats (ng/g) (n = 6).
Compound Group T(min)
1 10
BZP Control 110.69± 27.18 26.48± 5.16
MCAO 63.17± 18.02 25.66± 6.78
Br-NBP Control 334.35± 65.65 547.77± 103.85
MCAO 648.33± 53.90** 1569.26± 421.69*
*P < 0.05, compared with control; ** P < 0.01, compared with control.
FIGURE 8 | Plasma protein binding profile of BZP. (n = 3, mean ± SD).
39.0min) indicated that BZP had fewer side effects (Li et al.,
2014). The other pharmacokinetic parameters (t1/2, Vz, and
CL) were not agreement in 1–4 mg/kg, which probably because
of the short t1/2 value and individual differences. Unlike rats,
there was no gender difference on the major pharmacokinetic
parameters of BZP and Br-NBP in dogs. Furthermore, the
AUC0–t ratio of BZP/Br-NBP were 1.66, 1.63, and 1.06 for 1,
2, and 4mg/kg. No remarkable difference was found among 1–
2mg/kg, but the AUC0–t ratio of BZP/Br-NBP in 4mg/kg was
lower than in 1, 2mg/kg, suggesting that the dose level has an
impact on the transformation of BZP to Br-NBP. After multiple
administration of BZP to beagle dogs, the pharmacokinetic
parameters and plasma concentrations of BZP and Br-NBP
between day 1 and day 7 showed no difference, which indicated
that there was no accumulation of BZP and Br-NBP in the
plasma of beagle dogs. In a word, the pharmacokinetics of
BZP in beagle dogs was quite different from that observed in
rats.
Tissue distribution is vital for understanding the major target
sites of the drug and provides the information of its disposition
in vivo, which is closely related to the toxicity and efficacy
(Mekjaruskul et al., 2012; Kim et al., 2014). Therefore it is
essential to investigate the tissue distribution of BZP and Br-
NBP. The sampling points selected for tissue distribution study
were in distribution, metabolism and elimination phase. The
results demonstrated that BZP and Br-NBP underwent rapid
and wide distribution to tissues. The concentration of BZP
and Br-NBP in most of the tissues decreased obviously in
110min, indicating that there was no long-term accumulation,
and this concentration variation trend was congruent with
that in the plasma. The concentration of BZP in lung, small
intestine, and spleen were significantly higher than in other
tissues. The highest concentration level of Br-NBP were observed
in kidney, lung, liver, heart, which demonstrated that blood
flow and perfusion rate of the organ played a key role in
the distribution (Shi et al., 2014). The distributions of BZP
and Br-NBP were different in major tissues, which could be
attributed to the molecules’ different solubility proprieties or
specific transporters in each tissue (Wagner et al., 2016). In
addition, BZP was detectable at a rather low concentration in
the brain which illustrated that BZP could transfer across the
blood-brain barrier (BBB) and consequently exert significant
effect on brain. Additionally, the AUC0–t ratios of BZP/Br-
NBP were different in different tissues, which demonstrated the
ability and rates of transformation were different. The above
results demonstrated that BZP could convert to Br-NBP in rat
plasma and tissue through a spontaneous pathway. Br-NBP could
be further metabolized into hydroxylation metabolites in liver
microsomes by CYP450s (data not shown), while the mechanism
of metabolism and excretion still need for further investigation.
It is well accepted that drug’s effects is closely related to
its target concentration (Billard, 2015). For the purpose of
investigating the brain distribution of BZP, we performed further
study in MCAO rats, a widely accepted model (Walberer and
Rueger, 2015). The results demonstrated the concentrations of
BZP were similar in two kinds of rats, there was no significant
difference between normal and MCAO rats for the distribution
of BZP as its high polar. In addition, the concentration of BZP
was largely lower than Br-NBP, which may on account of the high
lipid solubility of Br-NBP and spatial structure of halogen atom.
Besides, the concentration of Br-NBP in MCAO rats was higher
than in normal rats. Experimental and clinical evidence proved
that BBB after cerebral ischemia was disrupted and permeability
was increased (Ren et al., 2015; Yan et al., 2015). Furthermore,
as selective distribution of 10-OH-NBP and 3-OH-NBP (the
hydroxylatedmetabolites of NBP) across the BBB of rats is mainly
attributed to the differences in plasma and brain protein binding
and the eﬄux transport of 3-OH-NBP (Diao et al., 2015), the
protein binding also could influence the brain distribution.
Plasma protein binding plays a key role in development
of pharmacokinetics/pharmacodynamics relationships
and prediction of drug–drug interaction potential,
potency/selectivity/toxicity, and so on (Riccardi et al., 2015).
Pharmacokinetic properties such as hepatic metabolism,
distribution volume, and membrane transport are highly
related to the unbound fraction of drugs (Tang et al., 2006).
Drug-drug interactions may occur by the reason of protein
binding displacement, particularly for high protein-binding
(>90%) drugs. Such as the anticoagulant drug warfarin, the
protein binding rate was about 99%. Lipid-lowering statin drugs
fluvastatin (commonly co-administered with warfarin) could
significantly displace plasma protein binding of warfarin and
induce drug-drug interactions (Shaik et al., 2016). The protein
bindings of BZP from various species plasma were different. BZP
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was more strongly bound to rat and dog plasma than human
plasma. However, the plasma binding of BZP in human plasma
was not too high, which indicated the drug-drug interactions
could not induced by plasma protein binding displacement.
CONCLUSION
As a promising agent, the preclinical DMPK data of BZP would
be an important asset to exploit its huge therapeutic potential for
treatment of ischemic stroke. In present study, the PK profiles
of BZP were detailedly assessed in rats and beagle dogs. In
conclusion, BZP and Br-NBP showed (A) short half-life, (B) dose
linear pharmacokinetic profile, (C) wide tissue distribution, (D)
different degree protein binding to various species plasma. The
present findings provide valuable information with regards to the
experimental PK properties of BZP and Br-NBP in rats and beagle
dogs, which serve as a firm basis for further investigation of BZP
in both preclinical and clinical phase.
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